Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): A phase II trial

C. Gridelli, F. Perrone, C. Gallo, A. Rossi, E. Barletta, M. L. Barzelloni, S. Creazzola, T. Gatani, F. Fiore, C. Guida, F. Scognamiglio

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background: Although the use of salvage chemotherapy in advanced non-small cell lung cancer (NSCLC) is controversial, pretreated symptomatic patients often need some kind of treatment to achieve symptoms relief. Gemcitabine is one of the most active new drugs in advanced NSCLC and preliminary reports suggest that it is active also in patients previously treated with platinum compounds. Aim: to evaluate activity and toxicity and the effect on quality of life of gemcitabine in platinum-pretreated patients with advance NSCLC. Methods: single-stage phase 2 trial with p0 = 5%, p1 = 20%, alfa = 5%, beta = 10%; 34 patients required and 4 objective responses expected to warrant further studies. Gemcitabine was administered at dose of 1000 mg/m2, i.v., d 1-8-15, every 4 weeks, for a maximum of 6 cycles. Quality of life was measured by EORTC C-30 and LC-13 questionnaires. Results: from September 1996 to July 1998, 30 patients have been enrolled. There were 6 (20% exact 95% CI 8-39%) partial responses (2 responses were in pts with brain metastases and 2 in patients progressed during first-line chemotherapy). All patients (but one died because myocardial infarction) progressed; median time to progression was 10 weeks (95% CI 7-12); 28 patients died; median survival was 22 weeks (95% CI 17-29). Quality of life analysis showed no significant change but for the improvement of cough after 3 cycles of chemotherapy. There was no severe toxicity. Conclusion: gemcitabine is active as second line for patients with advanced NSCLC who received platinum-based first line treatment. In view of such results randomized trials comparing gemcitabine versus best supportive care are warranted.

Original languageEnglish
Pages (from-to)4535-4538
Number of pages4
JournalAnticancer Research
Volume19
Issue number5 C
Publication statusPublished - 1999

Fingerprint

gemcitabine
Non-Small Cell Lung Carcinoma
Therapeutics
Quality of Life
Platinum
Drug Therapy
Platinum Compounds
Cough

Keywords

  • Gemcitabine
  • Non small cell lung cancer
  • Phase II study
  • Second line chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gridelli, C., Perrone, F., Gallo, C., Rossi, A., Barletta, E., Barzelloni, M. L., ... Scognamiglio, F. (1999). Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): A phase II trial. Anticancer Research, 19(5 C), 4535-4538.

Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC) : A phase II trial. / Gridelli, C.; Perrone, F.; Gallo, C.; Rossi, A.; Barletta, E.; Barzelloni, M. L.; Creazzola, S.; Gatani, T.; Fiore, F.; Guida, C.; Scognamiglio, F.

In: Anticancer Research, Vol. 19, No. 5 C, 1999, p. 4535-4538.

Research output: Contribution to journalArticle

Gridelli, C, Perrone, F, Gallo, C, Rossi, A, Barletta, E, Barzelloni, ML, Creazzola, S, Gatani, T, Fiore, F, Guida, C & Scognamiglio, F 1999, 'Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): A phase II trial', Anticancer Research, vol. 19, no. 5 C, pp. 4535-4538.
Gridelli, C. ; Perrone, F. ; Gallo, C. ; Rossi, A. ; Barletta, E. ; Barzelloni, M. L. ; Creazzola, S. ; Gatani, T. ; Fiore, F. ; Guida, C. ; Scognamiglio, F. / Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC) : A phase II trial. In: Anticancer Research. 1999 ; Vol. 19, No. 5 C. pp. 4535-4538.
@article{9e4a5cddfbb24c37905bade0eb4ded96,
title = "Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): A phase II trial",
abstract = "Background: Although the use of salvage chemotherapy in advanced non-small cell lung cancer (NSCLC) is controversial, pretreated symptomatic patients often need some kind of treatment to achieve symptoms relief. Gemcitabine is one of the most active new drugs in advanced NSCLC and preliminary reports suggest that it is active also in patients previously treated with platinum compounds. Aim: to evaluate activity and toxicity and the effect on quality of life of gemcitabine in platinum-pretreated patients with advance NSCLC. Methods: single-stage phase 2 trial with p0 = 5{\%}, p1 = 20{\%}, alfa = 5{\%}, beta = 10{\%}; 34 patients required and 4 objective responses expected to warrant further studies. Gemcitabine was administered at dose of 1000 mg/m2, i.v., d 1-8-15, every 4 weeks, for a maximum of 6 cycles. Quality of life was measured by EORTC C-30 and LC-13 questionnaires. Results: from September 1996 to July 1998, 30 patients have been enrolled. There were 6 (20{\%} exact 95{\%} CI 8-39{\%}) partial responses (2 responses were in pts with brain metastases and 2 in patients progressed during first-line chemotherapy). All patients (but one died because myocardial infarction) progressed; median time to progression was 10 weeks (95{\%} CI 7-12); 28 patients died; median survival was 22 weeks (95{\%} CI 17-29). Quality of life analysis showed no significant change but for the improvement of cough after 3 cycles of chemotherapy. There was no severe toxicity. Conclusion: gemcitabine is active as second line for patients with advanced NSCLC who received platinum-based first line treatment. In view of such results randomized trials comparing gemcitabine versus best supportive care are warranted.",
keywords = "Gemcitabine, Non small cell lung cancer, Phase II study, Second line chemotherapy",
author = "C. Gridelli and F. Perrone and C. Gallo and A. Rossi and E. Barletta and Barzelloni, {M. L.} and S. Creazzola and T. Gatani and F. Fiore and C. Guida and F. Scognamiglio",
year = "1999",
language = "English",
volume = "19",
pages = "4535--4538",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 C",

}

TY - JOUR

T1 - Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC)

T2 - A phase II trial

AU - Gridelli, C.

AU - Perrone, F.

AU - Gallo, C.

AU - Rossi, A.

AU - Barletta, E.

AU - Barzelloni, M. L.

AU - Creazzola, S.

AU - Gatani, T.

AU - Fiore, F.

AU - Guida, C.

AU - Scognamiglio, F.

PY - 1999

Y1 - 1999

N2 - Background: Although the use of salvage chemotherapy in advanced non-small cell lung cancer (NSCLC) is controversial, pretreated symptomatic patients often need some kind of treatment to achieve symptoms relief. Gemcitabine is one of the most active new drugs in advanced NSCLC and preliminary reports suggest that it is active also in patients previously treated with platinum compounds. Aim: to evaluate activity and toxicity and the effect on quality of life of gemcitabine in platinum-pretreated patients with advance NSCLC. Methods: single-stage phase 2 trial with p0 = 5%, p1 = 20%, alfa = 5%, beta = 10%; 34 patients required and 4 objective responses expected to warrant further studies. Gemcitabine was administered at dose of 1000 mg/m2, i.v., d 1-8-15, every 4 weeks, for a maximum of 6 cycles. Quality of life was measured by EORTC C-30 and LC-13 questionnaires. Results: from September 1996 to July 1998, 30 patients have been enrolled. There were 6 (20% exact 95% CI 8-39%) partial responses (2 responses were in pts with brain metastases and 2 in patients progressed during first-line chemotherapy). All patients (but one died because myocardial infarction) progressed; median time to progression was 10 weeks (95% CI 7-12); 28 patients died; median survival was 22 weeks (95% CI 17-29). Quality of life analysis showed no significant change but for the improvement of cough after 3 cycles of chemotherapy. There was no severe toxicity. Conclusion: gemcitabine is active as second line for patients with advanced NSCLC who received platinum-based first line treatment. In view of such results randomized trials comparing gemcitabine versus best supportive care are warranted.

AB - Background: Although the use of salvage chemotherapy in advanced non-small cell lung cancer (NSCLC) is controversial, pretreated symptomatic patients often need some kind of treatment to achieve symptoms relief. Gemcitabine is one of the most active new drugs in advanced NSCLC and preliminary reports suggest that it is active also in patients previously treated with platinum compounds. Aim: to evaluate activity and toxicity and the effect on quality of life of gemcitabine in platinum-pretreated patients with advance NSCLC. Methods: single-stage phase 2 trial with p0 = 5%, p1 = 20%, alfa = 5%, beta = 10%; 34 patients required and 4 objective responses expected to warrant further studies. Gemcitabine was administered at dose of 1000 mg/m2, i.v., d 1-8-15, every 4 weeks, for a maximum of 6 cycles. Quality of life was measured by EORTC C-30 and LC-13 questionnaires. Results: from September 1996 to July 1998, 30 patients have been enrolled. There were 6 (20% exact 95% CI 8-39%) partial responses (2 responses were in pts with brain metastases and 2 in patients progressed during first-line chemotherapy). All patients (but one died because myocardial infarction) progressed; median time to progression was 10 weeks (95% CI 7-12); 28 patients died; median survival was 22 weeks (95% CI 17-29). Quality of life analysis showed no significant change but for the improvement of cough after 3 cycles of chemotherapy. There was no severe toxicity. Conclusion: gemcitabine is active as second line for patients with advanced NSCLC who received platinum-based first line treatment. In view of such results randomized trials comparing gemcitabine versus best supportive care are warranted.

KW - Gemcitabine

KW - Non small cell lung cancer

KW - Phase II study

KW - Second line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0033428330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033428330&partnerID=8YFLogxK

M3 - Article

C2 - 10650806

AN - SCOPUS:0033428330

VL - 19

SP - 4535

EP - 4538

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 C

ER -